Gene Delivery at World Nano 2027

Gene delivery, a cutting-edge frontier in biomedical research, offers transformative prospects for genetic medicine. The ability to introduce therapeutic genes into target cells holds immense promise for treating genetic disorders and chronic diseases at their core. Among the promising carriers, nanoparticles, particularly liposomes and viral vectors, demonstrate efficiency in gene delivery. Liposomes, characterized by a lipid bilayer structure, provide a biocompatible and versatile platform for encapsulating genetic material. These nanoscale vesicles safeguard genetic cargo during transport and facilitate its controlled release into cells. Ongoing advancements in surface modifications enhance their targeting precision, ensuring specific delivery to diseased tissues while minimizing off-target effects.

Viral vectors, derived from viruses, leverage the natural capability of viruses to invade host cells. Adeno-associated viruses (AAVs) and lentiviruses are notable vectors, offering stable gene expression. However, safety concerns and potential immunogenicity necessitate continuous research to refine these delivery systems. Recent breakthroughs, such as CRISPR-Cas9 gene editing technology, have further propelled gene delivery into a new era. This revolutionary tool enables precise modification of genetic sequences, providing unprecedented control over gene expression. Integrating CRISPR-Cas9 with sophisticated delivery systems enhances the potential for targeted and personalized therapeutic interventions. As the field of gene delivery advances, interdisciplinary collaborations between molecular biologists, materials scientists, and clinicians become increasingly pivotal. Overcoming existing challenges in scalability, safety, and delivery efficiency will be instrumental in translating gene-based therapies from the laboratory to clinical applications.